6 stories found
Innovent Biologics released earnings data highlighting robust revenue from GLP-1 drugs and announced ambitious revenue projections for 2030, prompting a 15% upward revision in fair value estimates.
Pfizer has entered into a deal worth up to $10.5 billion with China's Innovent Biologics to develop next-generation cancer therapies, marking a significant collaboration in the pharmaceutical sector.
Several companies, including The Marzetti Company, Citi Trends, Tuniu, and Vipshop, released their Q2 or Q4 2026 earnings reports. While some companies like Marzetti and Tuya topped revenue estimates, others like Selectquote and Tuniu reported misses or weak guidance.
Pfizer has entered into a significant oncology deal with China's Innovent Biologics, valued at up to $10.5 billion. The agreement involves collaboration on 12 cancer drug trials, boosting Innovent Biologics' shares.
Innovent Biologics and Eli Lilly have partnered to commercialize Verzenios (abemaciclib) in China, expanding access to the cancer treatment in the region.
Metalla Royalty & Streaming has announced its financial results for the full fiscal year.